We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+15.52%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$482M
AUM Growth
+$99.4M
Cap. Flow
+$8.71M
Cap. Flow %
1.81%
Top 10 Hldgs %
61.57%
Holding
55
New
16
Increased
8
Reduced
12
Closed
12
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.5 years

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Miscellaneous 22.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.52B
$44.1M 9.14%
+290,000
New +$35.2M
2019 Q2
0 quarters
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.8B
$43.9M 9.1%
+500,000
New +$42.6M
2019 Q2
0 quarters
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$443B
$37.3M 7.75%
+200,000
New +$36.8M
2019 Q2
0 quarters
BPMC icon
4
DELISTED
Blueprint Medicines
BPMC
$35.4M 7.34%
375,000
+135,000
+56% +$11.1M
2019 Q1
1 quarter
MRTX
5
DELISTED
Mirati Therapeutics
MRTX
$34.5M 7.16%
335,000
+185,000
+123% +$14.4M
2017 Q4
6 quarters
ASND icon
6
Ascendis Pharma
ASND
$16.8B
$25.9M 5.37%
225,000
-160,000
-42% -$19.1M
2017 Q3
7 quarters
AXSM icon
7
Axsome Therapeutics
AXSM
$7.14B
$21.9M 4.54%
850,000
+540,000
+174% +$10.8M
2019 Q1
1 quarter
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$3.04B
$20M 4.16%
750,000
-150,000
-17% -$3.83M
2018 Q1
5 quarters
FOLD icon
9
DELISTED
Amicus Therapeutics
FOLD
$18.1M 3.75%
1,450,000
+150,000
+12% +$1.9M
2018 Q4
2 quarters
GBT
10
DELISTED
Global Blood Therapeutics
GBT
$15.8M 3.27%
300,000
– –
2018 Q2
4 quarters
ARGX icon
11
argenx
ARGX
$59.2B
$14.2M 2.94%
+100,000
New +$12.7M
2019 Q2
0 quarters
IMMU
12
CALL
DELISTED
Immunomedics
IMMU
$11.1M 2.3%
+800,000
New +$12M
2019 Q2
0 quarters
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$19.8B
$10.9M 2.26%
150,000
– –
2018 Q2
4 quarters
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$1.88B
$9.48M 1.97%
2,500,000
+2,000,000
+400% +$12M
2018 Q3
3 quarters
RARX
15
DELISTED
Ra Pharmaceuticals
RARX
$9.02M 1.87%
300,000
– –
2019 Q1
1 quarter
FXF icon
16
Invesco CurrencyShares Swiss Franc Trust
FXF
$360M
$8.75M 1.82%
92,200
+400
+0.4% +$37K
2018 Q3
3 quarters
IMMU
17
DELISTED
Immunomedics
IMMU
$8.32M 1.73%
600,000
-200,000
-25% -$3.01M
2016 Q2
12 quarters
CBAY icon
18
DELISTED
Cymabay Therapeutics
CBAY
$7.16M 1.49%
1,000,000
+250,000
+33% +$2.83M
2019 Q1
1 quarter
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$236M
$6.9M 1.43%
460,000
-140,000
-23% -$2.44M
2017 Q4
6 quarters
KALV icon
20
DELISTED
KalVista Pharmaceuticals
KALV
$6.64M 1.38%
300,000
-100,000
-25% -$2.35M
2018 Q3
3 quarters
VRAY
21
DELISTED
ViewRay
VRAY
$6.61M 1.37%
750,000
– –
2017 Q2
8 quarters
MIST icon
22
Milestone Pharmaceuticals
MIST
$49.7M
$6.52M 1.35%
+240,000
New +$4.95M
2019 Q2
0 quarters
PFE icon
23
PUT
Pfizer
PFE
$157B
$6.5M 1.35%
+158,100
New +$6.28M
2019 Q2
0 quarters
MNTA
24
DELISTED
Momenta Pharmaceuticals
MNTA
$6.22M 1.29%
500,000
– –
2018 Q4
2 quarters
ZYME icon
25
Zymeworks
ZYME
$1.86B
$6.05M 1.25%
+275,000
New +$5.05M
2019 Q2
0 quarters

Similar funds

Ghost Tree Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Ghost Tree Capital held 55 positions worth $482M, up 26% from $383M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Ghost Tree Capital's Q2 2019 filing shows 16 new, 8 increased, 12 reduced and 12 closed positions. Its largest new stake was Sarepta Therapeutics: 290,000 shares worth $44.1M. The largest sale was Ascendis Pharma, an estimated $19.1M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q2 2019 buy was Sarepta Therapeutics: 290,000 shares worth $44.1M.
  • Ghost Tree Capital added most to Mirati Therapeutics in Q2 2019, an estimated $14.4M increase.
  • Ghost Tree Capital's biggest Q2 2019 reduction was Ascendis Pharma, cutting an estimated $19.1M.
  • Ghost Tree Capital fully exited Vertex Pharmaceuticals in Q2 2019, selling an estimated $14.7M.
  • Ghost Tree Capital's ten largest holdings make up 62% of its $482M portfolio in Q2 2019.
  • Ghost Tree Capital opened 16 new positions and closed 12 in Q2 2019.
  • Ghost Tree Capital's portfolio value rose 26% quarter-over-quarter to $482M.

Based on Ghost Tree Capital's 13F filing for Q2 2019, filed 14 Aug 2019.